Pharmaceutical

Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review

The FDA has set 31 March 2024 as the PDUFA action date for reviewing odronextamab as third-line therapy for FL and DLBCL.

Sep 29, 2023 - 20:00
Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review
The FDA has set 31 March 2024 as the PDUFA action date for reviewing odronextamab as third-line therapy for FL and DLBCL.
Read the original article

Tags:

Previous Article

STAT+: Biogen shutters digital health group, nixes Apple study, as part of cost ...

Next Article

Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Lasers, cardiology, clinical trials: 2023’s top private equity targets

STAT+: Lasers, cardiology, clinical trials: 2023’s top ...

Feb 9, 2024

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Newly launched Calluna raises $81m to advance monoclona...

Jan 23, 2024

STAT+: The high hopes — and high stakes — behind Microsoft and Epic’s plan to use AI to answer patient questions

STAT+: The high hopes — and high stakes — behind Micros...

Apr 21, 2023